| Item Type | Name |
|
Concept
|
Vascular Endothelial Growth Factor C
|
|
Concept
|
Vascular Endothelial Growth Factor A
|
|
Concept
|
Receptor, Platelet-Derived Growth Factor beta
|
|
Concept
|
Endothelial Growth Factors
|
|
Concept
|
Vascular Endothelial Growth Factors
|
|
Concept
|
Receptors, Vascular Endothelial Growth Factor
|
|
Academic Article
|
SAVE (Super-dose anti-VEGF) trial: 2.0 mg ranibizumab for recalcitrant neovascular age-related macular degeneration: 1-year results.
|
|
Academic Article
|
Endophthalmitis after intravitreal injection: prevention and management.
|
|
Academic Article
|
Comparison of spectral-domain and time-domain optical coherence tomography in the detection of neovascular age-related macular degeneration activity.
|
|
Academic Article
|
Anti-vascular endothelial growth factor agents for pediatric retinal diseases.
|
|
Academic Article
|
Aflibercept treatment for patients with exudative age-related macular degeneration who were incomplete responders to multiple ranibizumab injections (TURF trial).
|
|
Academic Article
|
Neutralization of vascular endothelial growth factor slows progression of retinal nonperfusion in patients with diabetic macular edema.
|
|
Academic Article
|
Ranibizumab in preproliferative (ischemic) central retinal vein occlusion: the rubeosis anti-VEGF (RAVE) trial.
|
|
Academic Article
|
Progressive retinal nonperfusion in ischemic central retinal vein occlusion.
|
|
Academic Article
|
Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T.
|
|
Academic Article
|
Prospective Trial of Treat-and-Extend versus Monthly Dosing for Neovascular Age-Related Macular Degeneration: TREX-AMD 1-Year Results.
|
|
Academic Article
|
Reply: To PMID 24914476.
|
|
Academic Article
|
Aflibercept for pigment epithelial detachment for previously treated neovascular age-related macular degeneration.
|
|
Academic Article
|
DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema.
|
|
Academic Article
|
Predictors of Diabetic Macular Edema Treatment Frequency with Ranibizumab During the Open-Label Extension of the RIDE and RISE Trials.
|
|
Academic Article
|
Regulatory Factors Influencing Usage of Retinal Pharmaceuticals: A Look Both Home and Abroad.
|
|
Academic Article
|
Outcomes With As-Needed Aflibercept and Macular Laser Following the Phase III VISTA DME Trial: ENDURANCE 12-Month Extension Study.
|
|
Academic Article
|
Diagnostic and Therapeutic Challenges.
|
|
Academic Article
|
Reply.
|
|
Academic Article
|
Peripheral Laser for Recalcitrant Macular Edema Owing to Retinal Vein Occlusion: The WAVE Trial.
|
|
Academic Article
|
Impact of intravitreal pharmacotherapies including antivascular endothelial growth factor and corticosteroid agents on diabetic retinopathy.
|
|
Academic Article
|
Relationship Between Visual Acuity and Retinal Thickness During Anti-Vascular Endothelial Growth Factor Therapy for Retinal Diseases.
|
|
Academic Article
|
Distribution of Nonperfusion Area on Ultra-widefield Fluorescein Angiography in Eyes With Diabetic Macular Edema: DAVE Study.
|
|
Academic Article
|
Long-term outcomes with as-needed aflibercept in diabetic macular oedema: 2-year outcomes of the ENDURANCE extension study.
|
|
Academic Article
|
Intravitreal aflibercept for proliferative diabetic retinopathy.
|
|
Academic Article
|
Subfoveal choroidal thickness predicts macular atrophy in age-related macular degeneration: results from the TREX-AMD trial.
|
|
Academic Article
|
Optimizing Anti-VEGF Treatment Outcomes for Patients with Neovascular Age-Related Macular Degeneration.
|
|
Academic Article
|
Plasma Vascular Endothelial Growth Factor Concentrations after Intravitreous Anti-Vascular Endothelial Growth Factor Therapy for Diabetic Macular Edema.
|
|
Academic Article
|
Targeted Retinal Photocoagulation for Diabetic Macular Edema with Peripheral Retinal Nonperfusion: Three-Year Randomized DAVE Trial.
|
|
Academic Article
|
Changes in retinal ischaemic index correlate with recalcitrant macular oedema in retinal vein occlusion: WAVE study.
|
|
Academic Article
|
Longitudinal Quantification of Retinal Nonperfusion in the Macula of Eyes With Retinal Vein Occlusion Receiving Anti-VEGF Therapy: Secondary Analysis of the WAVE Randomized Trial.
|
|
Academic Article
|
Retinopathy Regression with Treat and Extend Ranibizumab for Diabetic Macular Edema.
|
|
Academic Article
|
Topographic Correspondence of Macular Atrophy With Choroidal Neovascularization in Ranibizumab-treated Eyes of the TREX-AMD Trial.
|
|
Academic Article
|
Ultra-Wide-Field Fluorescein Angiography-Guided Normalization of Ischemic Index Calculation in Eyes With Retinal Vein Occlusion.
|
|
Academic Article
|
When and How to Incorporate Steroids for Persistent Diabetic Macular Edema: A Discussion of Real-World Treatment Optimization Strategies.
|
|
Academic Article
|
Innovation in Neovascular Age-Related Macular Degeneration: Consideration of Brolucizumab, Abicipar, and the Port Delivery System.
|
|
Academic Article
|
Randomized Trial of Treat and Extend Ranibizumab With and Without Navigated Laser Versus Monthly Dosing for Diabetic Macular Edema: TREX-DME 2-Year Outcomes.
|
|
Academic Article
|
Simultaneous Inhibition of Angiopoietin-2 and Vascular Endothelial Growth Factor-A with Faricimab in Diabetic Macular Edema: BOULEVARD Phase 2 Randomized Trial.
|
|
Academic Article
|
Longitudinal Retinal Perfusion Status in Eyes with Diabetic Macular Edema Receiving Intravitreal Aflibercept or Laser in VISTA?Study.
|
|
Academic Article
|
Real-World Trends in Intravitreal Injection Practices among American Retina Specialists.
|
|
Academic Article
|
Relationship between duration and extent of oedema and visual acuity outcome with ranibizumab in diabetic macular oedema: A post hoc analysis of Protocol I data.
|
|
Academic Article
|
SEVERITY OF DIABETIC MACULAR EDEMA CORRELATES WITH RETINAL VASCULAR BED AREA ON ULTRA-WIDE FIELD FLUORESCEIN ANGIOGRAPHY: DAVE Study.
|
|
Academic Article
|
Relationship Between Retinal Fractal Dimension and Nonperfusion in Diabetic Retinopathy on Ultrawide-Field Fluorescein Angiography.
|
|
Academic Article
|
Intravitreal Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy: Outcomes from the Randomized RECOVERY Trial.
|
|
Academic Article
|
Quarterly Anti-Vascular Endothelial Growth Factor Dosing for Neovascular Age-Related Macular Degeneration: Real-World Clinical Outcomes.
|
|
Academic Article
|
Intravitreal Combined Aflibercept?+ Anti-Platelet-Derived Growth Factor Receptor ? for Neovascular Age-Related Macular Degeneration: Results of the Phase 2 CAPELLA Trial.
|
|
Academic Article
|
Assessment of the DRCR Retina Network Approach to Management With Initial Observation for Eyes With Center-Involved Diabetic Macular Edema and Good Visual Acuity: A Secondary Analysis of a Randomized Clinical Trial.
|
|
Academic Article
|
Thresholds for Initiating Treatment of Eyes with Diabetic Macular Edema and Good Vision: Consideration of DRCR.Net Protocol V Results.
|
|
Academic Article
|
RETINAL LEAKAGE INDEX DYNAMICS ON ULTRA-WIDEFIELD FLUORESCEIN ANGIOGRAPHY IN EYES TREATED WITH INTRAVITREAL AFLIBERCEPT FOR PROLIFERATIVE DIABETIC RETINOPATHY IN THE RECOVERY STUDY.
|
|
Academic Article
|
Loss to Follow-Up Among Patients With Proliferative Diabetic Retinopathy in Clinical Practice.
|
|
Academic Article
|
Long-term outcomes of treat-and-extend ranibizumab with and without navigated laser for diabetic macular oedema: TREX-DME 3-year results.
|
|
Academic Article
|
Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
|
|
Academic Article
|
Abicipar pegol for neovascular age-related macular degeneration.
|
|
Academic Article
|
Association of Intravitreal Aflibercept With Optical Coherence Tomography Angiography Vessel Density in Patients With Proliferative Diabetic Retinopathy: A Secondary Analysis of a Randomized Clinical Trial.
|
|
Academic Article
|
Visual Acuity Variability: Comparing Discrepancies between Snellen and ETDRS Measurements among Subjects Entering Prospective Trials.
|
|
Academic Article
|
Suprachoroidal CLS-TA plus Intravitreal Aflibercept for Diabetic Macular Edema: A Randomized, Double-Masked, Parallel-Design, Controlled Study.
|
|
Academic Article
|
Longitudinal panretinal microaneurysm dynamics on ultra-widefield fluorescein angiography in eyes treated with intravitreal aflibercept for proliferative diabetic retinopathy in the recovery study.
|
|
Academic Article
|
Effect of Aflibercept on Diabetic Retinopathy Severity and Visual Function in the RECOVERY Study for Proliferative Diabetic Retinopathy.
|
|
Academic Article
|
Aqueous Cytokine Expression and Higher Order OCT Biomarkers: Assessment of the Anatomic-Biologic Bridge in the IMAGINE DME Study.
|
|
Academic Article
|
Real-Time Photographic- and Fluorescein Angiographic-Guided Management of Diabetic Retinopathy: Randomized PRIME Trial Outcomes.
|
|
Academic Article
|
Intravitreal Aflibercept Injection vs Sham as Prophylaxis Against Conversion to Exudative Age-Related Macular Degeneration in High-risk Eyes: A Randomized Clinical Trial.
|
|
Academic Article
|
Brolucizumab vs aflibercept and ranibizumab for neovascular age-related macular degeneration: a cost-effectiveness analysis.
|
|
Academic Article
|
Exploring the angiographic-biologic phenotype in the IMAGINE study: quantitative UWFA and cytokine expression.
|
|
Academic Article
|
Evaluation of Intravitreal Aflibercept for the Treatment of Severe Nonproliferative Diabetic Retinopathy: Results From the PANORAMA Randomized Clinical Trial.
|
|
Academic Article
|
Morphological characteristics of eyes with neovascular age-related macular degeneration and good long-term visual outcomes after anti-VEGF therapy.
|
|
Academic Article
|
Early Residual Fluid-Free Status and Long-Term BCVA Outcomes: A Treatment Agnostic, Post Hoc Analysis of Pooled HAWK and HARRIER Data.
|
|
Academic Article
|
Safety Outcomes of Brolucizumab in Neovascular Age-Related Macular Degeneration: Results From the IRIS Registry and Komodo Healthcare Map.
|
|
Academic Article
|
NEW BIOMARKER QUANTIFYING THE EFFECT OF ANTI-VEGF THERAPY IN EYES WITH PROLIFERATIVE DIABETIC RETINOPATHY ON ULTRAWIDE FIELD FLUORESCEIN ANGIOGRAPHY: RECOVERY Study.
|
|
Academic Article
|
Treat-and-extend regimens of anti-vascular endothelial growth factor therapy for retinal vein occlusions: a systematic review and meta-analysis.
|
|
Academic Article
|
Antivascular endothelial growth factor agents for wet age-related macular degeneration: an IRIS registry analysis.
|
|
Academic Article
|
The 12- and 24-Month Effects of Intravitreal Ranibizumab, Aflibercept, and Bevacizumab on Intraocular Pressure: A Network Meta-Analysis.
|
|
Academic Article
|
EFFECT OF RETINAL THICKNESS VARIABILITY ON VISUAL OUTCOMES AND FLUID PERSISTENCE IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Post Hoc Analysis of the HAWK and HARRIER Studies.
|
|
Academic Article
|
Efficacy Outcomes of Brolucizumab Versus Aflibercept in Neovascular Age-Related Macular Degeneration Patients with Early Residual Fluid.
|
|
Academic Article
|
Retinal non-perfusion in diabetic retinopathy.
|
|
Academic Article
|
Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials.
|
|
Academic Article
|
Final Outcomes from the Randomized RECOVERY Trial of Aflibercept for Retinal Nonperfusion in Proliferative Diabetic Retinopathy.
|
|
Academic Article
|
Efficacy, safety, and treatment burden of treat-and-extend versus alternative anti-VEGF regimens for nAMD: a systematic review and meta-analysis.
|
|
Academic Article
|
Treat-and-extend versus alternate dosing strategies with anti-vascular endothelial growth factor agents to treat center involving diabetic macular edema: A systematic review and meta-analysis of 2,346 eyes.
|
|
Academic Article
|
MERLIN: Phase 3a, Multicenter, Randomized, Double-Masked Trial of Brolucizumab in Participants with Neovascular Age-Related Macular Degeneration and Persistent Retinal Fluid.
|
|
Academic Article
|
Role of anti-vascular endothelial growth factor in the management of non-proliferative diabetic retinopathy without centre-involving diabetic macular oedema: a meta-analysis of trials.
|
|
Academic Article
|
Frequency and timing of antivascular endothelial growth factor treatment for eyes with centre-involved diabetic macular oedema and good vision: Protocol V results in context.
|
|
Academic Article
|
Longitudinal analysis of aqueous humour cytokine expression and OCT-based imaging biomarkers in retinal vein occlusions treated with anti-vascular endothelial growth factor therapy in the IMAGINE study.
|
|
Academic Article
|
Favorable Anti-VEGF Crunch Syndrome: Nonsurgical Relief of Vitreoretinal Traction in Eyes With Proliferative Diabetic Retinopathy and Tractional Retinal Detachment.
|
|
Academic Article
|
INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR PHARMACEUTICAL UTILIZATION AND FINANCIAL IMPACT IN A VALUE-BASED CARE PROGRAM.
|
|
Academic Article
|
A Randomized Controlled Trial of OPT-302, a VEGF-C/D Inhibitor for Neovascular Age-Related Macular Degeneration.
|
|
Academic Article
|
Factors Linked to Injection Interval Extension in Eyes with Wet Age-Related Macular Degeneration Switched to Brolucizumab.
|
|
Academic Article
|
One-Year Brolucizumab Outcomes in Neovascular Age-Related Macular Degeneration from a Large United States Cohort in the IRIS? Registry.
|
|
Academic Article
|
Anti-vascular endothelial growth factor therapy and retinal non-perfusion in diabetic retinopathy: A meta-analysis of randomised trials.
|
|
Academic Article
|
KESTREL and KITE Phase 3 Studies: 100-Week Results With Brolucizumab in Patients With Diabetic Macular Edema.
|
|
Academic Article
|
Systematic review of efficacy and meta-analysis of safety of ranibizumab biosimilars relative to reference ranibizumab anti-VEGF therapy for nAMD treatment.
|
|
Academic Article
|
Longitudinal Quantitative Ultrawidefield Angiographic Features in Diabetic Retinopathy Treated with Aflibercept from the Intravitreal Aflibercept as Indicated by Real-Time Objective Imaging to Achieve Diabetic Retinopathy Improvement Trial.
|
|
Academic Article
|
Effect of High-Dose Intravitreal Aflibercept, 8 mg, in Patients With Neovascular Age-Related Macular Degeneration: The Phase 2 CANDELA Randomized Clinical Trial.
|
|
Academic Article
|
Subthreshold Compared with Threshold Macular Photocoagulation for Diabetic Macular Edema: A Systematic Review and Meta-Analysis.
|
|
Academic Article
|
Efficacy and Safety of Brolucizumab for Diabetic Macular Edema: The KINGFISHER Randomized Clinical Trial.
|
|
Academic Article
|
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial.
|